Three-fourths of patients have 70-75% improvement at 16 weeks with zasocitinib, envudeucit ...

Significantly less cancer-related cognitive impairment, mental fatigue after chemotherapy ...

Enrollment begins in Switzerland as the company continues to activate clinical sites beyond the U.S. market ANN ARBOR, Mich., March 16, 2026 /PRNewswire/ -- ONL Therapeutics, Inc., a clinical-stage ...

Starting treatment of study participants in the RASolute 303 trial represents an important milestone for our daraxonrasib program and for patients with metastatic pancreatic cancer, a disease with ...

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first patient in UPSTREAM SjD, a global, randomized, ...

Medtronic (NYSE:MDT) announced the launch of the EMBRACE trial of its Symplicity Spyral renal denervation (RDN) system.

FDA NDA submission for bezuclastinib targets post-imatinib GIST, using Real-Time Oncology Review and supported by prior ...

TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027Select TIGeR-PaC Cancer Centers ...

Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. antico ...

Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat ...

Patients with rheumatic heart disease who took the heart failure drug digoxin were 18% less likely to die or experience ...